Health Economics›Acute myeloid leukemia›Subsequent induction therapy standard and older "fit" patients

Subsequent induction therapy standard and older "fit" patients

Acute myeloid leukemia · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
DA 3+8 and GO Variant #01	—	R 54 262	8d	—	—	~1	~R 54 262 indirect	—
DA 3+8 Variant #01	—	R 13 255	10d	—	—	~1	~R 13 255 indirect	—

2 of 2 regimens shown